Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
30
ICCM Quote, Financials, Valuation and Earnings
Last price:
$0.57
Seasonality move
:
25.42%
Day range:
$0.59 - $0.62
52-week range:
$0.54 - $1.66
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
11.95x
P/B ratio:
4.38x
Volume:
65.8K
Avg. volume:
275.1K
1-year change:
-55.89%
Market cap:
$40.8M
Revenue:
$3.3M
EPS (TTM):
-$0.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ICCM
IceCure Medical Ltd.
|
$1.3M | -$0.04 | 196.97% | -49.43% | $3.13 |
|
LAB
Standard BioTools, Inc.
|
$18.5M | -$0.03 | -54.41% | -72.53% | $1.55 |
|
LUDG
Ludwig Enterprises, Inc.
|
-- | -- | -- | -- | -- |
|
NNOX
Nano-X Imaging Ltd.
|
$4M | -$0.15 | 33.13% | -35.84% | $7.40 |
|
XYLO
Xylo Technologies Ltd.
|
-- | -- | -- | -- | $9.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ICCM
IceCure Medical Ltd.
|
$0.59 | $3.13 | $40.8M | -- | $0.00 | 0% | 11.95x |
|
LAB
Standard BioTools, Inc.
|
$1.19 | $1.55 | $457.6M | -- | $0.00 | 0% | 3.50x |
|
LUDG
Ludwig Enterprises, Inc.
|
$0.0220 | -- | $3.6M | -- | $0.00 | 0% | 36,962.14x |
|
NNOX
Nano-X Imaging Ltd.
|
$2.24 | $7.40 | $146.5M | -- | $0.00 | 0% | 11.49x |
|
XYLO
Xylo Technologies Ltd.
|
$5.07 | $9.00 | $6.5M | -- | $3.94 | 0% | 0.13x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ICCM
IceCure Medical Ltd.
|
3% | -0.652 | 0.41% | 1.76x |
|
LAB
Standard BioTools, Inc.
|
6.41% | 0.841 | 5.49% | 1.93x |
|
LUDG
Ludwig Enterprises, Inc.
|
-144.65% | -0.654 | 24.05% | 0.00x |
|
NNOX
Nano-X Imaging Ltd.
|
4.79% | 1.591 | 3.26% | 3.82x |
|
XYLO
Xylo Technologies Ltd.
|
29.91% | -1.122 | 154.75% | 0.95x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ICCM
IceCure Medical Ltd.
|
$277K | -$3.8M | -195.32% | -217.45% | -451.29% | -$3.1M |
|
LAB
Standard BioTools, Inc.
|
$9.5M | -$23.5M | -22.34% | -24.44% | -120.02% | -$23.1M |
|
LUDG
Ludwig Enterprises, Inc.
|
-- | -$371.4K | -- | -- | -419868.12% | -$139.1K |
|
NNOX
Nano-X Imaging Ltd.
|
-$3M | -$14.2M | -31.33% | -32.75% | -412.88% | -$13.9M |
|
XYLO
Xylo Technologies Ltd.
|
-- | -- | -40.15% | -51.7% | -- | -- |
IceCure Medical Ltd. vs. Competitors
-
Which has Higher Returns ICCM or LAB?
Standard BioTools, Inc. has a net margin of -454% compared to IceCure Medical Ltd.'s net margin of -162.05%. IceCure Medical Ltd.'s return on equity of -217.45% beat Standard BioTools, Inc.'s return on equity of -24.44%.
Company Gross Margin Earnings Per Share Invested Capital ICCMIceCure Medical Ltd.32.59% -$0.06 $9.6M LABStandard BioTools, Inc.48.51% -$0.09 $427M -
What do Analysts Say About ICCM or LAB?
IceCure Medical Ltd. has a consensus price target of $3.13, signalling upside risk potential of 428.68%. On the other hand Standard BioTools, Inc. has an analysts' consensus of $1.55 which suggests that it could grow by 30.25%. Given that IceCure Medical Ltd. has higher upside potential than Standard BioTools, Inc., analysts believe IceCure Medical Ltd. is more attractive than Standard BioTools, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ICCMIceCure Medical Ltd.1 0 0 LABStandard BioTools, Inc.1 2 0 -
Is ICCM or LAB More Risky?
IceCure Medical Ltd. has a beta of 0.979, which suggesting that the stock is 2.136% less volatile than S&P 500. In comparison Standard BioTools, Inc. has a beta of 1.290, suggesting its more volatile than the S&P 500 by 28.967%.
-
Which is a Better Dividend Stock ICCM or LAB?
IceCure Medical Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IceCure Medical Ltd. pays -- of its earnings as a dividend. Standard BioTools, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICCM or LAB?
IceCure Medical Ltd. quarterly revenues are $850K, which are smaller than Standard BioTools, Inc. quarterly revenues of $19.6M. IceCure Medical Ltd.'s net income of -$3.9M is higher than Standard BioTools, Inc.'s net income of -$31.7M. Notably, IceCure Medical Ltd.'s price-to-earnings ratio is -- while Standard BioTools, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IceCure Medical Ltd. is 11.95x versus 3.50x for Standard BioTools, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICCMIceCure Medical Ltd.11.95x -- $850K -$3.9M LABStandard BioTools, Inc.3.50x -- $19.6M -$31.7M
-
Which has Higher Returns ICCM or LUDG?
Ludwig Enterprises, Inc. has a net margin of -454% compared to IceCure Medical Ltd.'s net margin of -427991.3%. IceCure Medical Ltd.'s return on equity of -217.45% beat Ludwig Enterprises, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ICCMIceCure Medical Ltd.32.59% -$0.06 $9.6M LUDGLudwig Enterprises, Inc.-- -- -$1.4M -
What do Analysts Say About ICCM or LUDG?
IceCure Medical Ltd. has a consensus price target of $3.13, signalling upside risk potential of 428.68%. On the other hand Ludwig Enterprises, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that IceCure Medical Ltd. has higher upside potential than Ludwig Enterprises, Inc., analysts believe IceCure Medical Ltd. is more attractive than Ludwig Enterprises, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ICCMIceCure Medical Ltd.1 0 0 LUDGLudwig Enterprises, Inc.0 0 0 -
Is ICCM or LUDG More Risky?
IceCure Medical Ltd. has a beta of 0.979, which suggesting that the stock is 2.136% less volatile than S&P 500. In comparison Ludwig Enterprises, Inc. has a beta of 2.470, suggesting its more volatile than the S&P 500 by 146.979%.
-
Which is a Better Dividend Stock ICCM or LUDG?
IceCure Medical Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ludwig Enterprises, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IceCure Medical Ltd. pays -- of its earnings as a dividend. Ludwig Enterprises, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICCM or LUDG?
IceCure Medical Ltd. quarterly revenues are $850K, which are larger than Ludwig Enterprises, Inc. quarterly revenues of --. IceCure Medical Ltd.'s net income of -$3.9M is lower than Ludwig Enterprises, Inc.'s net income of $31.3K. Notably, IceCure Medical Ltd.'s price-to-earnings ratio is -- while Ludwig Enterprises, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IceCure Medical Ltd. is 11.95x versus 36,962.14x for Ludwig Enterprises, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICCMIceCure Medical Ltd.11.95x -- $850K -$3.9M LUDGLudwig Enterprises, Inc.36,962.14x -- -- $31.3K
-
Which has Higher Returns ICCM or NNOX?
Nano-X Imaging Ltd. has a net margin of -454% compared to IceCure Medical Ltd.'s net margin of -396.98%. IceCure Medical Ltd.'s return on equity of -217.45% beat Nano-X Imaging Ltd.'s return on equity of -32.75%.
Company Gross Margin Earnings Per Share Invested Capital ICCMIceCure Medical Ltd.32.59% -$0.06 $9.6M NNOXNano-X Imaging Ltd.-86.42% -$0.21 $164.6M -
What do Analysts Say About ICCM or NNOX?
IceCure Medical Ltd. has a consensus price target of $3.13, signalling upside risk potential of 428.68%. On the other hand Nano-X Imaging Ltd. has an analysts' consensus of $7.40 which suggests that it could grow by 230.36%. Given that IceCure Medical Ltd. has higher upside potential than Nano-X Imaging Ltd., analysts believe IceCure Medical Ltd. is more attractive than Nano-X Imaging Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ICCMIceCure Medical Ltd.1 0 0 NNOXNano-X Imaging Ltd.4 0 0 -
Is ICCM or NNOX More Risky?
IceCure Medical Ltd. has a beta of 0.979, which suggesting that the stock is 2.136% less volatile than S&P 500. In comparison Nano-X Imaging Ltd. has a beta of 1.312, suggesting its more volatile than the S&P 500 by 31.211%.
-
Which is a Better Dividend Stock ICCM or NNOX?
IceCure Medical Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nano-X Imaging Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IceCure Medical Ltd. pays -- of its earnings as a dividend. Nano-X Imaging Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICCM or NNOX?
IceCure Medical Ltd. quarterly revenues are $850K, which are smaller than Nano-X Imaging Ltd. quarterly revenues of $3.4M. IceCure Medical Ltd.'s net income of -$3.9M is higher than Nano-X Imaging Ltd.'s net income of -$13.7M. Notably, IceCure Medical Ltd.'s price-to-earnings ratio is -- while Nano-X Imaging Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IceCure Medical Ltd. is 11.95x versus 11.49x for Nano-X Imaging Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICCMIceCure Medical Ltd.11.95x -- $850K -$3.9M NNOXNano-X Imaging Ltd.11.49x -- $3.4M -$13.7M
-
Which has Higher Returns ICCM or XYLO?
Xylo Technologies Ltd. has a net margin of -454% compared to IceCure Medical Ltd.'s net margin of --. IceCure Medical Ltd.'s return on equity of -217.45% beat Xylo Technologies Ltd.'s return on equity of -51.7%.
Company Gross Margin Earnings Per Share Invested Capital ICCMIceCure Medical Ltd.32.59% -$0.06 $9.6M XYLOXylo Technologies Ltd.-- -- $22.4M -
What do Analysts Say About ICCM or XYLO?
IceCure Medical Ltd. has a consensus price target of $3.13, signalling upside risk potential of 428.68%. On the other hand Xylo Technologies Ltd. has an analysts' consensus of $9.00 which suggests that it could grow by 77.52%. Given that IceCure Medical Ltd. has higher upside potential than Xylo Technologies Ltd., analysts believe IceCure Medical Ltd. is more attractive than Xylo Technologies Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ICCMIceCure Medical Ltd.1 0 0 XYLOXylo Technologies Ltd.1 0 0 -
Is ICCM or XYLO More Risky?
IceCure Medical Ltd. has a beta of 0.979, which suggesting that the stock is 2.136% less volatile than S&P 500. In comparison Xylo Technologies Ltd. has a beta of 0.321, suggesting its less volatile than the S&P 500 by 67.93%.
-
Which is a Better Dividend Stock ICCM or XYLO?
IceCure Medical Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xylo Technologies Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $3.94 per share. IceCure Medical Ltd. pays -- of its earnings as a dividend. Xylo Technologies Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICCM or XYLO?
IceCure Medical Ltd. quarterly revenues are $850K, which are larger than Xylo Technologies Ltd. quarterly revenues of --. IceCure Medical Ltd.'s net income of -$3.9M is higher than Xylo Technologies Ltd.'s net income of --. Notably, IceCure Medical Ltd.'s price-to-earnings ratio is -- while Xylo Technologies Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IceCure Medical Ltd. is 11.95x versus 0.13x for Xylo Technologies Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICCMIceCure Medical Ltd.11.95x -- $850K -$3.9M XYLOXylo Technologies Ltd.0.13x -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
40
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
91
TDC alert for Feb 12
Teradata Corp. [TDC] is down 11.64% over the past day.
Buy
67
DIOD alert for Feb 12
Diodes, Inc. [DIOD] is down 7.63% over the past day.
Buy
77
VRT alert for Feb 12
Vertiv Holdings Co. [VRT] is down 4.79% over the past day.
